Preventive treatments for breast cancer: recent developments

被引：6

作者：

Ales-Martinez, J. E. ^{[1
]}

Ruiz, A. ^{[2
]}

Chacon, J. I. ^{[3
]}

Lluch Hernandez, A. ^{[4
]}

Ramos, M. ^{[5
]}

Cordoba, O. ^{[6
]}

Aguirre, E. ^{[7
]}

Barnadas, A. ^{[8
]}

Jara, C. ^{[9
]}

Gonzalez, S. ^{[10
]}

Plazaola, A. ^{[11
]}

Florian, J. ^{[12
]}

Andres, R. ^{[13
]}

Sanchez Rovira, P. ^{[14
]}

Frau, A. ^{[15
]}

机构：

[1] Hosp Nuestra Senora de Sonsoles, GEICAM Spanish Breast Canc Grp, Avila, Spain

[2] GEICAM Spanish Breast Canc Grp, IVO, Valencia, Spain

[3] Hosp Virgen Salud, GEICAM Spanish Breast Canc Grp, Toledo, Spain

[4] Univ Valencia, Hosp Clin Univ Valencia INCLIVA, GEICAM Spanish Breast Canc Grp, Valencia, Spain

[5] GEICAM Spanish Breast Canc Grp, Ctr Oncol Galicia, La Coruna, Spain

[6] Hosp Univ Vall dHebron, GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[7] Hosp Arnau Vilanova, GEICAM Spanish Breast Canc Grp, Lleida, Spain

[8] Hosp Santa Creu & Sant Pau, GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[9] Hosp Univ Fdn Alcorcon, GEICAM Spanish Breast Canc Grp, Madrid, Spain

[10] Hosp San Pedro de Alcantara, GEICAM Spanish Breast Canc Grp, Caceres, Spain

[11] GEICAM Spanish Breast Canc Grp, Onkol, Guipuzcua, Spain

[12] Hosp Barbastro, GEICAM Spanish Breast Canc Grp, Huesca, Spain

[13] Hosp Clin Univ Lozano Blesa, GEICAM Spanish Breast Canc Grp, Zaragoza, Spain

[14] Complejo Hosp Jaen, GEICAM Spanish Breast Canc Grp, Jaen, Spain

[15] Hosp Prov Castellon, GEICAM Spanish Breast Canc Grp, Castellon de La Plana, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2015年 / 17卷 / 04期

关键词：

Breast cancer; Pharmacological prevention; GEICAM; Aromatase inhibitors; BRCA; Breast cancer prevention; SURGICAL ADJUVANT BREAST; BOWEL PROJECT; RISK; TAMOXIFEN; WOMEN; CHEMOPREVENTION; RALOXIFENE; MODEL; PREDICTION; EXEMESTANE;

D O I：

10.1007/s12094-014-1250-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated.

引用

页码：257 / 263

页数：7

共 28 条

[1]

Ales JE, 2011, 13 C NAC SEOM MAL 19

[2] Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia [J].

Boughey, Judy C. ;

Hartmann, Lynn C. ;

Anderson, Stephanie S. ;

Degnim, Amy C. ;

Vierkant, Robert A. ;

Reynolds, Carol A. ;

Frost, Marlene H. ;

Pankratz, V. Shane .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3591-3596

[3] The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions [J].

Coopey, Suzanne B. ;

Mazzola, Emanuele ;

Buckley, Julliette M. ;

Sharko, John ;

Belli, Ahmet K. ;

Kim, Elizabeth M. H. ;

Polubriaginof, Fernanda ;

Parmigiani, Giovanni ;

Garber, Judy E. ;

Smith, Barbara L. ;

Gadd, Michele A. ;

Specht, Michelle C. ;

Guidi, Anthony J. ;

Roche, Constance A. ;

Hughes, Kevin S. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) :627-633

[4] Validation studies for models projecting the risk of invasive and total breast cancer incidence [J].

Costantino, JP ;

Gail, MH ;

Pee, D ;

Anderson, S ;

Redmond, CK ;

Benichou, J ;

Wieand, HS .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1541-1548

[5] Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial [J].

Cuzick, Jack ;

Forbes, John F. ;

Sestak, Ivana ;

Cawthorn, Simon ;

Hamed, Hisham ;

Holli, Kaija ;

Howell, Anthony .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (04) :272-282

[6] Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial [J].

Cuzick, Jack ;

Sestak, Ivana ;

Forbes, John F. ;

Dowsett, Mitch ;

Knox, Jill ;

Cawthorn, Simon ;

Saunders, Christobel ;

Roche, Nicola ;

Mansel, Robert E. ;

von Minckwitz, Gunter ;

Bonanni, Bernardo ;

Palva, Tiina ;

Howell, Anthony .

LANCET, 2014, 383 (9922) :1041-1048

[7] Preventive therapy for breast cancer: a consensus statement [J].

Cuzick, Jack ;

DeCensi, Andrea ;

Arun, Banu ;

Brown, Powel H. ;

Castiglione, Monica ;

Dunn, Barbara ;

Forbes, John F. ;

Glaus, Agnes ;

Howell, Anthony ;

von Minckwitz, Gunter ;

Vogel, Victor ;

Zwierzina, Heinz .

LANCET ONCOLOGY, 2011, 12 (05) :496-503

[8]

Ferlay J, 2012, CANC INC MORT WORLD

[9] Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].

Fisher, B ;

Costantino, JP ;

Wickerham, DL ;

Cecchini, RS ;

Cronin, WM ;

Robidoux, A ;

Bevers, TB ;

Kavanah, MT ;

Atkins, JN ;

Margolese, RG ;

Runowicz, CD ;

James, JM ;

Ford, LG ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (22) :1652-1662

[10] Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older [J].

Freedman, Andrew N. ;

Yu, Binbing ;

Gail, Mitchell H. ;

Costantino, Joseph P. ;

Graubard, Barry I. ;

Vogel, Victor G. ;

Anderson, Garnet L. ;

McCaskill-Stevens, Worta .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2327-2333

← 1 2 3 →